Member Info for Newuncle

Chiddy, nothing new there then, MMs play games with the spread and of course can ensure buys show as sells, some it's automatic and nothing to do with manipulation, partly correct yes it is automated but the spread is set by the MMs and are buy/sell prices, see it all the time.

Dr Christophe Chassagnole (Physiomics PLC)

“Here at the University of Leeds, I see continued focus on interdisciplinary, translational projects, with ever-growing teams from a wide spectrum of research fields. An area of significant current interest, and one I am engaging in, is the interaction of nutrition with health, disease, and therapy. As a chemist, I can see multiple ways to contribute to these inquiries. Finally, I would observe that the pandemic and the success of the vaccine programmes have encouraged large numbers of applications to study biomedical-focused courses at university. This means there will soon be an increase in highly motivated and well-qualified graduates entering the employment market in our field, which is an exciting opportunity for those who are ready!”

Notably for ValiRx, subsidiary Inaphaea BioLabs Ltd launched during the first half of 2023. It is part of ValiRx's translational contract research organisation and is based in Nottingham. Translational means that ValiRx focuses on enabling the translation of innovative science into clinical development.

"Following its launch, Inaphaea has continued to build the translational contract research organisation concept by developing collaborations with companies that provide complementary capabilities, such as Physiomics [PLC], Oncobone [Ltd] and, more recently, Agility Life Sciences [Ltd]. Their services, when aligned with the cell-based testing of Inaphaea, present a very compelling service offering to companies seeking to translate preclinical assets into clinical candidates, including ValiRx's own development pipeline

Should be interesting?

It has been a busy time for Inaphaea as we welcomed new faces and partnerships in preparation for the highly anticipated lab launch on 26 September.

And this too:

https://www.inaphaea.com/inaphaea-biolabs-secures-first-external-contract

Thought this looks interesting fwiw

https://www.valirx.com/news/meet-valirx-scientific-advisory-board

Bound to see people taking quick profits today, I expect we will see plenty more buying action later, off for a bit, back later, look after the BB and watch out for those trolls who are bound to turn up eventually.

Results due end of the month should make make for really interesting reading and hopefully a good steer on what's come here.

He should and I expect he will

Correction, I should of course said "not often" doh!

Laura you often get the chance to get on at the bottom on a business like this. Currently people are trading it on the price movements, I am holding and adding for the big time to come here. Either PYC will grow exponentially itself or get taken out by a major.

One question I have for you and K, is do or could PYC licence it's solution to the likes of Merck? Now that would be areal game changer imo if PYC could earn licence fees by letting a major industry player do all the leg work getting much wider market recognition and sales and PYC could get paid over and over again?

What I really like about this company is it's association with pharma sector exposure drugs development which is always growing but without the risk of actually relying on developing the drugs (and the never ending testing/approval required)....could be a licence to print money here for PYC?

Expect we could see some resistance at 3p as traders exit......but buyers seem keen as mustard so who knows

Offer is printed at 3p

+25% 3p looming

Can sell but NT to buy

Wow +20%

L they will have to reissue that rns as we are in 2023

Does no one check these rns releases?

Brighty they had 57m at 30p = £17m mcap!

Brighty thanks for me it's always the relevant mcap that counts as number of shares will have changed. Can you work out that mcap when the shares hit those prices?

Tia